DK2543357T3 - Sammensætning til brug til behandling og forebyggelse af inflammationsrelaterede lidelser - Google Patents
Sammensætning til brug til behandling og forebyggelse af inflammationsrelaterede lidelser Download PDFInfo
- Publication number
- DK2543357T3 DK2543357T3 DK11173000.8T DK11173000T DK2543357T3 DK 2543357 T3 DK2543357 T3 DK 2543357T3 DK 11173000 T DK11173000 T DK 11173000T DK 2543357 T3 DK2543357 T3 DK 2543357T3
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- inflammation
- drug
- disease
- mesalamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/15—Suppositories
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
- SAMMENSÆTNING TIL BRUG TIL BEHANDLING OG FOREBYGGELSE AF INFLAMMATIONSRELATEREDE LIDELSER1. Sammensætning til brug til behandling eller forebyggelse af en slimhindeinflammation hos et pattedyr eller menneske omfattende et lægemiddelstof egnet til behandling af en inflammation i en dosis, der er lavere end den normale terapeutiske dosis deraf, og hyaluronsyre (HA) eller HA-blanding, hvori det antiinflammatoriske lægemiddelstof er mesalamin og den reducerede terapeutiske dosis er fra 250 mg til 1 g pr. dag, hvori slimhinden med slimhindeinflammation er en slimhinde i gastrointestinalkanalen.
- 2. Sammensætning ifølge krav 1, hvori HA’en er af en gennemsnitlig molekylevægt (Mw) mellem 50 kilo Dalton og 5 mio. kilo Dalton.
- 3. Sammensætning ifølge krav 1, hvori HA-blandingen omfatter mindst to hyaluronsyrer, herunder HA med lav gennemsnitlig molekylevægt (LMWHA) og HA med høj gennemsnitlig molekylevægt (HMWHA), hvori den gennemsnitlige Mw af LMWHA’en er mellem 50 kilo Da og 1,5 mio. Da, og den gennemsnitlige Mw af HMWHA’en er mellem 1,5 mio. kilo Da og 5 mio. kilo Da, hvori LMWHA’en og HMWHA’en er adskilt fra hinanden med mindst 0,5 mio. Da, og blandingsforholdet mellem LMWHA’en og HMWHA’en er i området fra 20:80 til 80:20 efter vægt.
- 4. Sammensætning ifølge krav 1, som fremstilles ved at danne naturlig fysisk eller kemisk kraft mellem HA og lægemiddelstoffet, hvori den fysiske eller kemiske kraft tilvejebringes ved chelering, elektrostatisk interaktion, adhæsion for at danne en polymer eller en globeformet indkapsling.
- 5. Sammensætning ifølge krav 1, hvori den slimhindeinflammationsrelaterede lidelse er gastroesofageal refluxsygdom (GERD), esofagitis, gastritis, enteritis, peptisk sår, inflammatorisk tarmsygdom (IBD), Crohns sygdom, irritabel tyktarm (IBS), intestinal inflammation, proktitis eller eosinofil gastroenteritis.
- 6. Sammensætning ifølge krav 1, yderligere omfattende et hjælpestoftil formulering af sammensætningen til en administrationsdoseringsform til gastrointestinalkanalen.
- 7. Sammensætning ifølge krav 6, hvori administrationsdoseringsformen til gastrointestinalkanalbrug er valgt fra gruppen bestående af fast doseringsform, perfusion, enema, suppositorium og opløsning herunder suspension.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11173000.8A EP2543357B1 (en) | 2011-07-07 | 2011-07-07 | Composition for use in treating and preventing inflammation related disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2543357T3 true DK2543357T3 (da) | 2018-07-02 |
Family
ID=44512628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11173000.8T DK2543357T3 (da) | 2011-07-07 | 2011-07-07 | Sammensætning til brug til behandling og forebyggelse af inflammationsrelaterede lidelser |
Country Status (18)
Country | Link |
---|---|
US (2) | US9370575B2 (da) |
EP (1) | EP2543357B1 (da) |
JP (1) | JP6100171B2 (da) |
KR (1) | KR20130121893A (da) |
CN (2) | CN107551273A (da) |
AU (1) | AU2012279133B2 (da) |
BR (1) | BR112013016950B8 (da) |
CA (1) | CA2820977C (da) |
DK (1) | DK2543357T3 (da) |
EA (1) | EA029905B1 (da) |
ES (1) | ES2667854T3 (da) |
HU (1) | HUE037474T2 (da) |
LT (1) | LT2543357T (da) |
NO (1) | NO2543357T3 (da) |
PL (1) | PL2543357T3 (da) |
PT (1) | PT2543357T (da) |
TW (1) | TWI533874B (da) |
WO (1) | WO2013006548A2 (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE037474T2 (hu) * | 2011-07-07 | 2018-08-28 | Holy Stone Healthcare Co Ltd | Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra |
EP2545925B1 (en) | 2011-07-12 | 2018-02-14 | Holy Stone Healthcare Co.,Ltd. | Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases |
KR101412776B1 (ko) | 2013-03-11 | 2014-07-01 | 가톨릭대학교 산학협력단 | 각결막염 치료용 점안제 조성물 및 이의 제조 방법 |
US9539265B2 (en) | 2013-03-15 | 2017-01-10 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
WO2014142938A1 (en) * | 2013-03-15 | 2014-09-18 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
WO2015076294A1 (ja) * | 2013-11-22 | 2015-05-28 | キユーピー株式会社 | 薬剤の副作用である胃潰瘍の発症抑制方法、および胃潰瘍発症が抑制された経口薬剤組成物ならびにその製造方法 |
CN103655601B (zh) * | 2013-12-31 | 2019-10-25 | 上海建华精细生物制品有限公司 | 一种用于膀胱灌洗的组合物 |
EP2985027B1 (en) | 2014-08-16 | 2021-03-31 | Church & Dwight Co., Inc. | Nasal composition comprising mixture of hyaluronic acids and saline solution |
EP2985019B1 (en) | 2014-08-16 | 2021-10-20 | Church & Dwight Co., Inc. | Nasal composition having anti-viral properties |
EA202092471A1 (ru) * | 2018-04-18 | 2021-03-25 | Ай.КОМ МЕДИКАЛ ГМБХ | Высокомолекулярная гиалуроновая кислота для улучшения выживания эпителия и восстановления поверхностей тела |
IT201800007683A1 (it) * | 2018-07-31 | 2020-01-31 | Altergon Sa | Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati |
CN109924485A (zh) * | 2019-03-29 | 2019-06-25 | 华熙生物科技股份有限公司 | 一种含透明质酸的减肥保健食品及其制备方法 |
CN110698925B (zh) * | 2019-10-16 | 2022-03-08 | 江苏科技大学 | 一种纳米印刷导电油墨组合物及其制备方法和应用 |
US11801127B2 (en) | 2020-04-07 | 2023-10-31 | Maurice Matthew Trentel | Method and system for a modular dental device |
IT202100021992A1 (it) * | 2021-08-27 | 2023-02-27 | Neilos S R L | Composizione per la prevenzione e/o il trattamento delle patologie gastriche ed esofagee |
CN116059241A (zh) * | 2021-11-04 | 2023-05-05 | 华熙生物科技股份有限公司 | 提高机体免疫力、促进胃肠道健康的含透明质酸或其盐的组合物及其应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1229075B (it) | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
EP0259485A4 (en) | 1986-03-14 | 1988-07-29 | Bio Technology General Corp | HEAVY METAL SALTS OF HYALURONIC ACID FOR USE AS AN ANTIMICROBIAL AGENT. |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
JP2945993B2 (ja) * | 1989-12-05 | 1999-09-06 | 武田薬品工業株式会社 | 外用剤 |
US5095037B1 (en) * | 1989-12-21 | 1995-12-19 | Nissho Kk | Combined anti-inflammatory agent |
US5492936A (en) * | 1990-11-30 | 1996-02-20 | Allergan, Inc. | Bimodal molecular weight hyaluronate formulations and methods for using same |
ATE179329T1 (de) * | 1992-06-30 | 1999-05-15 | Procter & Gamble Pharma | Arzneimitteln zur behandlung von arthritis die phosphonate und nsaids enthalten |
CA2154103C (en) | 1995-07-18 | 1998-02-24 | Samuel Simon Asculai | Treatment of mucous membrane disease, trauma or condition and for the relief of pain |
JPH10226641A (ja) * | 1997-02-14 | 1998-08-25 | Kureha Chem Ind Co Ltd | 関節症治療製剤 |
US6551632B2 (en) * | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
CA2208924A1 (en) * | 1997-07-09 | 1999-01-09 | Hyal Pharmaceutical Corporation | Sparing paclitaxel by the use of hyaluronan |
DE60237363D1 (de) * | 2001-03-15 | 2010-09-30 | Soligenix Inc | Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden |
WO2002076448A1 (en) * | 2001-03-23 | 2002-10-03 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
EP1381361B1 (en) * | 2001-04-04 | 2009-02-25 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
US20030008844A1 (en) * | 2001-05-17 | 2003-01-09 | Keryx Biopharmaceuticals, Inc. | Use of sulodexide for the treatment of inflammatory bowel disease |
US20030171332A1 (en) | 2001-05-23 | 2003-09-11 | Abraham William M. | Treatment of respiratory conditions associated with bronchoconstriction with aerosolized hyaluronic acid |
JP4335005B2 (ja) * | 2001-10-18 | 2009-09-30 | 生化学工業株式会社 | 炎症性腸疾患処置剤 |
US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
DE10356248A1 (de) | 2003-11-13 | 2005-06-23 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden |
WO2005066214A1 (ja) * | 2004-01-07 | 2005-07-21 | Seikagaku Corporation | ヒアルロン酸誘導体及びそれを含む薬剤 |
US7417037B2 (en) * | 2004-01-20 | 2008-08-26 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
US7879818B2 (en) | 2005-12-23 | 2011-02-01 | Janos Borbely | Hyaluronic acid-based cross-linked nanoparticles |
ATE440609T1 (de) * | 2006-05-11 | 2009-09-15 | Sandra Gobbo | Binäre hyaluronsäure-gemische und ihre therapeutische verwendung |
MX2009000658A (es) * | 2006-07-19 | 2009-01-30 | Univ Texas | Preparaciones de fosfolipidos y componentes farmaceuticos que contienen acido 5-amino salicilico para el tratamiento de una enfermedad inflamatoria del intestino delgado. |
FR2919185B1 (fr) * | 2007-07-23 | 2010-09-10 | Ard Sa | Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de l'etat des muqueuses |
US8394782B2 (en) * | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
TWI383796B (zh) * | 2009-08-14 | 2013-02-01 | Holy Stone Healthcare Co Ltd | Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer |
TWI516269B (zh) * | 2009-08-14 | 2016-01-11 | 禾伸堂生技股份有限公司 | 使用於炎症性腸疾病(ibd)治療和預防之透明質酸混合物 |
US8575130B2 (en) * | 2010-01-04 | 2013-11-05 | Holy Stone Healthcare Co., Ltd. | Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease |
HUE037474T2 (hu) * | 2011-07-07 | 2018-08-28 | Holy Stone Healthcare Co Ltd | Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra |
-
2011
- 2011-07-07 HU HUE11173000A patent/HUE037474T2/hu unknown
- 2011-07-07 DK DK11173000.8T patent/DK2543357T3/da active
- 2011-07-07 EP EP11173000.8A patent/EP2543357B1/en active Active
- 2011-07-07 LT LTEP11173000.8T patent/LT2543357T/lt unknown
- 2011-07-07 PL PL11173000T patent/PL2543357T3/pl unknown
- 2011-07-07 NO NO11173000A patent/NO2543357T3/no unknown
- 2011-07-07 PT PT111730008T patent/PT2543357T/pt unknown
- 2011-07-07 ES ES11173000.8T patent/ES2667854T3/es active Active
-
2012
- 2012-06-27 TW TW101122966A patent/TWI533874B/zh active
- 2012-07-02 US US13/992,772 patent/US9370575B2/en active Active
- 2012-07-02 KR KR1020137016687A patent/KR20130121893A/ko active Search and Examination
- 2012-07-02 AU AU2012279133A patent/AU2012279133B2/en active Active
- 2012-07-02 BR BR112013016950A patent/BR112013016950B8/pt active IP Right Grant
- 2012-07-02 WO PCT/US2012/045238 patent/WO2013006548A2/en active Application Filing
- 2012-07-02 CN CN201710722519.4A patent/CN107551273A/zh active Pending
- 2012-07-02 CA CA2820977A patent/CA2820977C/en active Active
- 2012-07-02 CN CN2012800041922A patent/CN103260629A/zh active Pending
- 2012-07-02 EA EA201300608A patent/EA029905B1/ru unknown
- 2012-07-02 JP JP2013549623A patent/JP6100171B2/ja active Active
-
2018
- 2018-04-09 US US15/948,504 patent/US10471151B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PT2543357T (pt) | 2018-04-30 |
LT2543357T (lt) | 2018-06-11 |
KR20130121893A (ko) | 2013-11-06 |
WO2013006548A2 (en) | 2013-01-10 |
CN107551273A (zh) | 2018-01-09 |
EP2543357A1 (en) | 2013-01-09 |
CN103260629A (zh) | 2013-08-21 |
HUE037474T2 (hu) | 2018-08-28 |
US9370575B2 (en) | 2016-06-21 |
TW201302190A (zh) | 2013-01-16 |
NO2543357T3 (da) | 2018-08-18 |
BR112013016950B8 (pt) | 2023-10-10 |
WO2013006548A3 (en) | 2013-04-11 |
ES2667854T3 (es) | 2018-05-14 |
CA2820977A1 (en) | 2013-01-10 |
PL2543357T3 (pl) | 2018-08-31 |
JP2014502642A (ja) | 2014-02-03 |
US10471151B2 (en) | 2019-11-12 |
US20180221492A1 (en) | 2018-08-09 |
AU2012279133B2 (en) | 2015-08-20 |
BR112013016950B1 (pt) | 2023-04-11 |
EA201300608A1 (ru) | 2014-05-30 |
AU2012279133A1 (en) | 2013-07-04 |
NZ611857A (en) | 2015-09-25 |
US20140141077A1 (en) | 2014-05-22 |
EP2543357B1 (en) | 2018-03-21 |
EA029905B1 (ru) | 2018-05-31 |
TWI533874B (zh) | 2016-05-21 |
BR112013016950A2 (pt) | 2020-04-28 |
JP6100171B2 (ja) | 2017-03-22 |
CA2820977C (en) | 2016-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2543357T3 (da) | Sammensætning til brug til behandling og forebyggelse af inflammationsrelaterede lidelser | |
US10709731B2 (en) | Materials for treating and preventing mucosa related disease | |
EP2968195B1 (en) | Pharmaceutical formulation containing glycosaminoglycan | |
US20160193343A1 (en) | Composition for use in treating and preventing inflammation related disorder | |
US9539265B2 (en) | Pharmaceutical formulation containing glycosaminoglycan | |
NZ611857B2 (en) | Composition for use in treating and preventing inflammation related disorder | |
NZ613779B2 (en) | Materials for treating and preventing mucosa related disease |